Quigley granted key US patent for QR-333

27 August 2006

USA-based Quigley Pharma has been assigned patent no 7,083,813 B2, for its application - Methods for the Treatment of Peripheral Neural and Vascular Ailments - filed in November 2002. This adds another degree of intellectual property support to its lead investigational new drug, QR-333, currently in Phase II trials.

The company filed the patent application based on observations that subjects participating in the proof-of-concept study conducted in France using the QR-333 compound had further improvements over and above the existing protocol. A significant observation regarding the improved color of study patient's feet led Quigley to conclude that the topical application of the QR-333 compound may have led to improved peripheral circulation. This important new information provided the rationale for the company to file a separate patent application to protect its IP and allow it to study this further therapeutic benefit.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.